Table 5 Univariate analysis of potential prognostic factors for 5-year nadir + 2 biochemical outcome.
From: Image guided dose escalated prostate radiotherapy: still room to improve
| Risk Factor | Number |
Nadir +2 5-year bNED | p-value | HR (95%CI) |
|---|---|---|---|---|
| PSA | ||||
| <10 | 180 | 74.4% | ||
| 10-20 | 63 | 79.4% | ||
| >20 | 16 | 75% | ||
| Continuous variable | 0.85 | 1.00 (0.96-1.03) | ||
| Gleason grade | ||||
| 5-6 | 96 | 82.3% | 0.15 | (reference) |
| 7 | 141 | 71.6% | 0.06 | 1.73 (0.98-3.05) |
| 8-10 | 21 | 71.4% | 0.21 | 1.81 (0.71-4.59) |
| T-category | ||||
| T1b-T2a | 209 | 83.0% | 0.006 | (reference) |
| T2b-T2c | 43 | 64.9% | 0.002 | 2.48 (1.42-4.36) |
| T3a-TX | 7 | 68.6% | 0.56 | 1.56 (0.37-6.30) |
| Risk Grouping | ||||
| Low | 59 | 86.4% | 0.14 | 1 (reference) |
| Intermediate | 163 | 73% | 0.06 | 2.04 (0.96-4.34) |
| High | 37 | 70.3% | 0.07 | 2.33 (0.94-5.78) |
| Adjuvant Hormone | ||||
| No | 165 | 76.4% | 0.52 | 1 (reference) |
| Yes | 31 | 72.1% | 0.66 | 0.81 (0.43-1.53) |
| Age | ||||
| Continuous variable | 0.66 | 1.01(0.97-1.05) |